Business
Biomerica develops, patents, makes, and markets diagnostic and therapeutic products used with blood, urine, nasal, or fecal samples.
Biomerica is a small diagnostics company with FY2025 revenue down slightly, losses narrowing, weak margins, and an Altman distress signal.
The read at a glance✓ Audited against SEC data
- Business mix — Diagnostic and therapeutic productsNote
- Revenue — $5.3M, -1.9%Watch
- FCF — -$3.9MWatch
- Loss — Net loss narrowed 16.8%OK
- Equity — $4.1M, -37.7%Watch
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman distress; Beneish clean; EQ 84.7Watch
Where the revenue comes from
Fiscal 2026, as BIOMERICA INC reports it. History and quarterly detail are in the app.
- Clinical Lab$2.7M
- Contract Manufacturing$891K
- Over The Counte$821K
- Physicians Office$9K
Leadership changes
From BIOMERICA INC's own filings, the day they're filed.
- Cathy Coste · member · departureeff. 2025-06-04
- Jack Kenny · director · appointment
- Nasdaq Rule · director · appointment
Latest filings
- 10-K · Annual report2026-08-31
- 8-K · Company announcement2026-08-26
- 8-K · Company announcement2026-06-04
- 10-Q · Quarterly report2026-04-13
- 10-Q · Quarterly report2026-01-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BIOMERICA INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.